<DOC>
	<DOC>NCT02903836</DOC>
	<brief_summary>Study to Determine the Safety, Tolerability, Pharmacokinetics and Efficacy of Oral Nafithromycin Versus Oral Moxifloxacin in the Treatment of Community-Acquired Bacterial Pneumonia (CABP) in Adults</brief_summary>
	<brief_title>Phase II Study of Oral Nafithromycin in CABP</brief_title>
	<detailed_description />
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia, Bacterial</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
	<criteria>Meet the clinical criteria for CABP based on following: 1. Clinical symptoms (new or worsening) 2. Vital sign abnormalities 3. Laboratory abnormalities 4. Radiographic evidence of CABP 5. PORT score 1. Subjects with any of the following confirmed or suspected types of pneumonia: 1. Aspiration pneumonia 2. Hospitalacquired bacterial pneumonia (HABP) 3. Healthcareassociated bacterial pneumonia (HCAP) 4. Ventilatorassociated bacterial pneumonia (VABP) 5. Pneumonia that may be caused by pathogen(s) resistant to either study drug 2. Receipt of 1 or more dose(s) of a potentially effective systemic antibacterial treatment for treatment of the current CABP 3. Suspected or confirmed noninfectious causes of pulmonary infiltrates 4. Subjects requiring concomitant adjunctive or additional potentiallyeffective systemic antibacterial treatment for management of CABP</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>